Log In
BCIQ
Print this Print this
 

Soltamox, tamoxifen

  Manage Alerts
Collapse Summary General Information
Company Perrigo Co. plc
DescriptionLiquid formulation of tamoxifen citrate
Molecular Target Estrogen receptor 1 (ESR1)
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer; Treat hormonally sensitive breast cancer; Treat metastatic breast cancer
Regulatory Designation
PartnerMidatech Pharma plc;
Mission Pharmacal Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$311.0M

$283.6M

$5.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today